E. Krognes - Feb 9, 2022 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
CFO and Treasurer
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Feb 9, 2022
Transactions value $
-$48,073
Form type
4
Date filed
2/11/2022, 04:20 PM
Previous filing
Jan 7, 2022
Next filing
Feb 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$48.1K -1.3K -1.04% $37.09 123K Feb 9, 2022 Direct F1, F2, F3
holding DNLI Common Stock 850K Feb 9, 2022 See footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $36.75 to $37.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 94608 restricted stock units.
F4 The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.